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Pandemic influenza virusA(H1N1) 2009was associatedwith a higher risk of viral pneumonia in comparisonwith seasonal influenza
viruses.The influenza season 2011-2012 was characterized by the prevalent circulation of influenza A(H3N2) viruses.Whereas most
H3N2 patients experiencedmild, self-limited influenza-like illness, some patients were at increased risk for influenza complications
because of age or underlyingmedical conditions. Cases presentedwere patients admitted to the Intensive CareUnit (ICU) of ECMO
referral center (Careggi TeachingHospital, Florence, Italy). Despite extracorporealmembrane oxygenation treatment (ECMO), one
patient with H3N2-induced ARDS did not survive. Our experience suggests that viral aetiology is becoming more important and
hospitals should be able to perform a fast differential diagnosis between bacterial and viral aetiology.
1. Introduction
Influenza viruses represent an important cause of severe
lower respiratory disease. Pandemic influenza virus A(H1N1)
2009 was associated with a higher risk of viral pneumonia
in comparison with seasonal influenza viruses [1, 2]. During
the pandemic and the following influenza epidemic season
2010-2011, this led to an increased frequency of hospitaliza-
tion in Intensive Care Units (ICUs) and of Acute Respiratory
Distress Syndrome (ARDS) that is the most severe type of
acute lung injury. The influenza season 2011-2012 was char-
acterized by the prevalent circulation of influenza A(H3N2)
viruses.Whereas most H3N2 patients experiencedmild, self-
limited influenza-like illness, some patients were at increased
risk for influenza complications because of age or underlying
medical conditions.
Here we show our experience of treating two cases of
adult patient with ARDS due to H3N2 pneumonia treated
with venovenous extracorporeal membrane oxygenation
(ECMO).
2. Methods
2.1. Setting. The patients were admitted to the Intensive Care
Unit (ICU) of Careggi Teaching Hospital (Florence, Italy)
as ECMO Referral Center in season 2011-2012. Data were
collected from ICU databases and the Italian Group for
the Evaluation of Interventions in Intensive Care Medicine
database (GiViTI Margherita Project, Istituto Mario Negri,
Bergamo, Italy). Table 1 summarized baseline and clinical
characteristic of patients. Internal Review Board approved
the study and informed consent for data publication was
obtained.
2.2. Ventilation Strategies and Extracorporeal Membrane
Oxygenation (ECMO). ECMO was used to support the
respiratory function after the failure of standard protec-
tive ventilation strategy (6mL/kg tidal volume normalized
on ideal body weight and plateau pressure lower than
30 cmH
2
O). The positive end-expiratory pressure (PEEP)
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Table 1: Clinical characteristic of H3N2-pneumonia patients.
Patient Age(years) Gender
Body
mass
index
Comorbidity
PaO2
(mmHg)/FIO
ratio at
admission
Oxygenation index:
mean airway pressure
(cmH2O) ∗ FIO2∗ 100/PaO2
(mmHg)
Mechanical
ventilation
duration
(days)
ECMO
support
ICU
length of
stay
Outcome
M. G. 66 Male 24
Rheumatoid
arthritis,
Sjogren
Syndrome
107 15 30 Yes 30 Nonsurvived
F. M. 76 Male 26
Diabetes
Mellitus,
arteriopathy
80 6 20 Yes 23 Survived
applied was fixed at lower flex in the pressure/volume curve
[3]. ECMO treatments were venovenous (Maquet Rotaflow
Centrifugal Pumps with Quadrox-D oxygenators, Maquet,
Rastatt, Germany) and biocoated circuits were used. Avalon
double lumen cannulas (Avalon Elite Bi-Caval Dual Lumen
Catheter 27-31 Fr., Avalon Laboratories, Rancho Dominguez,
CA, USA) were inserted through internal right jugular
vein. Cannulas position was confirmed by transesophageal
echocardiography [3].
2.3. Laboratory Tests. Influenza virus identification and typ-
ing was performed by RT-real time PCR, using specific
set of primers and specific TaqMan probes (following the
indications of the Italian National Influenza Centre, National
Health Institute, Rome).The primers and the probes targeted,
respectively, a sequence of M gene specific for influenza
type A viruses, of M gene specific for type B influenza,
and different sequences of HA gene, each specific for the
seasonal H3 and H1 subtype. In addition, for the detection
of the pandemic H1 2009 virus, the set of primers and probe
proposed by the Centers for Disease Control and Prevention
were used [4]. The RT-real time PCR for the M gene of
influenza type A viruses was employed as a quantitative assay
to assess the load of virus shedding, using serial dilution of
an RNA standard prepared in our laboratory. This calibrator
consisted of the RNA sequence transcribed by the T7 RNA
polymerase on the template of the product of the real time
amplification of the M gene, cloned in the pGEM-T Easy
Vector (Promega).
3. Cases Presentation
3.1. Patient 1. M. G., a 66-year-old man in treatment with
immunosuppressive drugs due to rheumatologic diseases,
experienced cough and sneezing in the beginning without
other symptoms. He was not vaccinated against influenza.
Clinical conditions had beenworsening for a few days, so that
the patient was admitted to a local hospital for respiratory
distress after 19 days from initial symptoms. At Emergency
Department (ED) admission, he was hypoxic, with clinical
and radiological signs of ARDS and he was immediately
transferred to the ICU. After 6 days our ECMO center
was contacted; patient was then evaluated on-site by the
mobile ECMO-team and ECMO treatment was started in the
peripheral hospital. The patient was transferred to Careggi
Hospital in Florence.
Diagnostic imaging showed an improvement of consol-
idation areas of upper pulmonary lobes and an increase of
interstitial lung disease without pleural effusion. Echocardio-
graphy showed mild pulmonary hypertension. PCR assays
made on pharyngeal swab and bronchoalveolar lavage were
positive for viral genomes of H3N2 virus (105 copies/mL).
Bronchoalveolar lavage resulted negative for bacterial aeti-
ology. Oseltamivir (10mg twice) was initiated. From day 8
onwards, lung functions and imaging improved and ECMO
weaning was started until ECMO-off (zero gas flow) for 12
hours. On day 11, ECMO system was removed.
After ECMO removal, the patient remained on sup-
portive mechanical ventilation and he was cooperative and
able to perform respiratory physiotherapy. As consequence
of pulmonary inflammation, patient developed progressive
pulmonary fibrosis and pulmonary hypertension. Moreover,
PCR for CMV was found positive (11014 copies), and ther-
apy with ganciclovir was started. Five days after ECMO
removal, the patient showed a septic exacerbation with
fever up to 39∘C, increased laboratory markers of infection,
and worsened gas exchange which needed an increase in
ventilator support.The following day, the patient’s respiratory
and, consequently, hemodynamic status deteriorated despite
increasing ventilator setting. A high dosage of inotropes
was required.Microbiological examination showed a positive
PCR for HSV1. The treatment with specific antiviral drugs
was unsuccessful and the patient developed multiple organ
failures and after 18 days of post-ECMO removal the patient
died.
3.2. Patient 2. F. M., a 76-years-old man, experienced fever
(as high as 40∘), cough, and dyspnoea for 3 days. He was not
vaccinated against influenza and the patient was referred to
ED because of persisting of respiratory symptoms. The CT-
scan performed before admission showed extensive consol-
idations mostly at the superior right lobe and both inferior
lobes. In both throat swab and bronchoalveolar lavage PCR
for influenza virus A(H3N2) was positive (105 copies/mL),
so oseltamivir was initiated. Bronchoalveolar lavage resulted
negative for bacterial aetiology. For the worsening of gas
exchange and patient’s respiratory fatigue, clinicians pro-
ceeded to intubation and mechanical ventilation. For the
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persistent severe hypoxemia despite high PEEP levels, after
three days the decision to start venovenous ECMOwasmade.
During ECMO treatment the patient was kept mildly
sedated and he was ventilated with lung protective mode.
No major complication occurred during ECMO treatment.
Respiratory exchange improved and weaning from ECMO
was started and ended after 8 days when ECMO system
was removed. After various spontaneous breathing trials,
he was able to maintain spontaneous breathing and he was
discharged after 23 days of ICU stay.
4. Discussion
In pandemic 2009 influenza A(H1N1), many patients devel-
oped critical illness and needed to be treated with ECMO [5].
In our experience during pandemic 2009 influenza A(H1N1)
[6] we observed a low mortality rate in H1N1-induced ARDS
patients, as also reported in larger series of H1N1 patients
[7–9], if compared to bacterial ARDS. This difference can
be attributed mainly to the fact that H1N1 respiratory failure
presents a relatively benign course when adequately treated,
if compared to non-H1N1-induced ARDS, even when ECMO
was necessary.
During the influenza epidemic season 2011-2012, we
had two cases of severe respiratory infection caused by
seasonal influenza A viruses, subtype H3N2, slightly differ-
ent from the vaccine virus A/Perth/16/2009, belonging to
the clade A/Victoria/208/2009. In these patients, the H3N2
virus induced severe inflammation and epithelial necrosis
of bronchi and bronchioles with extension into the alveoli
causing diffuse alveolar damage. This process leads to ARDS.
This observation strengthens what our experience, following
the H1N1 pandemic [10], strongly suggests that the screening
for influenza virus should be performed systematically in ICU
patients during seasonal influenza epidemics, in particular
from November to March [11].
5. Conclusions
Viral aetiology of acute respiratory failure is becoming
more relevant, especially in young and old compromised
people. Our cases show influenza A(H3N2) viruses as one
of the factors causing pneumonia associated to significant
morbidity and mortality.
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